Medication Updates

2015 Medication Updates
2014 Medication Updates
2013 Medication Updates
General Resources:

FDA approves Aristada (aripiprazole lauroxil) to treat schizophrenia
FDA approved Aristada extended release injection to treat adults with schizophrenia.

FDA approves Vraylar (cariprazine) to treat schizophrenia and bipolar disorder
Vraylar capsules approved to treat schizophrenia and bipolar disorder in adults.

FDA modifies monitoring for neutropenia in patients using clozapine; approves new REMS program
The FDA is changing the requirements for clozapine to address safety concerns about neutropenia, a serious blood condition. The FDA also approves new shared REMS program to improve monitoring and treatment of patients with severe neutropenia.

FDA approves first drug treatment for sexual desire disorder
The FDA has approved Addyi (flibanserin) to treat acquired, generalized hypoactive sectual desire disorder (HSDD) in premenopausal women.
FDA warns of name confusion with Brintellix (vortioxetine) and Brilinta (ticagrelor)
Reports of confusion between Brintellix (an antidepressant) and Brilinta (an anti-blood clotting medication) have resulted in the wrong medication being prescribed or dispensed.
FDA approves Rexulti (brexpiprazole) to treat schizophrenia and as an add-on for major depressive disorder
Rexulti approved to treat adults with schizophrenia and as an add-on with antidepressants for major depressive disorder.
FDA warns of counterfeiting issue with Diazepam purchased online
Diazepam purchased on the internet runs the potential risk of being counterfeit, the FDA reports. 700 adverse reactions have been reported in patients taking mislabeled Diazepam.
FDA reports permanent skin-color changes with use of Daytrana patch (methylphenidate transdermal system)
The FDA is warning that use of the Daytrana patch (methylphenidate transdermal system) for ADHD may lead to permanent loss of skin color.
First Generic Abilify (aripiprazole) approved by FDA
Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder.
New Guidance on Medication-Assisted Treatment for Alcohol Use Disorder
SAMHSA guide for expanding use of medication in clinical practice for the treatment of alcohol use disorder.
FDA expands uses of Vyvanse to treat binge-eating disorder
Vynase (lisdexamfetamine dimesylate) is now approved to treat binge-eating disorder in adults.
FDA reviews Zyprexa Relprevv
The FDA study of two deaths associated with the injectable schizophrenia drug Zyprexa Relprevv were inconclusive.
Extended-Release Injectable Naltrexone
New SAMHSA guidance on the use of medication assisted treatment with extended-release injectable naltrexone for the treatment of opioid use disorder.
Ziprasidone: FDA Warning
FDA reporting mental health drug ziprasidone (Geodon) associated with rare but potentially fatal skin reactions.
FDA approves Hysingla ER
This extended-release, single-entity hydrocodone product has abuse-deterrent properties
Recall of Effexor issued by Manufacturer
Sun Pharmaceutical Industries Ltd. recalled 68,000 bottles of venlafaxine (Effexor) this week, according to a report in the Wall Street Journal.
Sleep Drug Belsomra approved by FDA
Approved for use as needed to treat insomnia. Belsomra is the first orexin receptor antagonist to be approved.
FDA approves Targiniq ER
Targiniq ER is an extended-release pain reliever with abuse-deterrent properties - contains oxycodone and naloxone.
First-Generation vs Second-Generation Antipsychotics in Adults: Comparative Effectiveness
AHRQ clinician summary of systematic review examining their comparative effectiveness, benefits, and adverse effects.
Tramadol placed in Schedule IV of Controlled Substances Act
Schedule IV controlled substances regulatory requirements apply to tramadol as of 8/18/14.
FDA approves Farxiga to treat type 2 diabetes
Farxiga (dapaglifozin) tablets to improve glycemic control in adults with type 2 diabetes.
FDA approves Tanzeum to treat type 2 diabetes
Tanzeum is a glucagon-like peptide-1 receptor agonist that helps normalize blood sugar levels.
Lunesta/Eszopiclone Containing Sleep Aids
FDA warns that Lunesta can cause next-day impairment. Recommended starting dose of1 mg at bedtime.
FDA approves hand-held auto-injector to reverse opioid overdose
Evzio delivers a single dose of naloxone via hand-held auto-injector
Methylphenidate ADHD Medications: Risk of Priapism
FDA warns that methylphenidate products may in rare instances cause priapism.
Opioids Effective for Restless Legs Syndrome
Study found that prolonged-release opioid treatment relieved symptoms of severe restless legs syndrome.
National Drug Threat Assessment
DEA looks at challenges communities face related to drug abuse and trafficking.
Generic Versions of Cymbalta Approved
FDA approved first generic versions of Cymbalta (duloxetine delayed-release capsules), used to treat depression and other conditions.
Zyprexa Relprevv
FDA investigating 2 unexplained deaths in patients who received intramuscular injection of antipsychotic drug.
Federal Guidelines for Managing Occupational Exposures to HIV
PEP regimens in the guidelines encourage consistent use of a combination of 3 or more drugs that are better tolerated
FDA approved label changes specifying new dosing recommendations.
SAMHSA DAWN Report: Increase in Emergency Department visits for adverse reactions involving Zolpidem
FDA approves abuse-deterrent labeling for reformulated OxyContin.
Antipsychotics in Adults
Clinician summary on antipsychotics for schizophrenia and bipolar disorder


The American Psychiatric Nurses Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.